Munich (Germany), Heidelberg (Germany) – June 22, 2010 – BICOLL GmbH, a biopharmaceutical
drug discovery company specializing in high-tech natural product chemistry to identify novel small
molecules for drug discovery and related innovative fields and EMBL, the renowned international and
inter-governmental research organisation, focusing on molecular biology and biophysics, today
announce the successful completion of a joint research project on the identification of active compounds as inhibitors of aurora kinases.